The Trapidil Eluting Coronary DES which elutes the drug Trapidil. The Intrepide is mounted on a Nimbus Pico catheter which allows for better access to the most complex lesions. A number of clinical studies has shown that Trapidil has four primary modes of action when given orally namely, anti-proliferative , anti-thrombotic and anti-inflammatory. Trapidil was initially developed in 1971 and was initially used as a vasodilator. Studies have found Trapidil to be a potent inhibitor of platelet aggregation and activation, vascular smooth muscle cell proliferation, and monocyte/macrophage migration and activation, thereby making it a potentially potent anti-restoretic agent. The Trapidil Eluting Coronary DES features delivery, efficacy, safety and stability making it the lowest of any DES currently available on market today.